Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00625612 · ClinicalTrials.gov registry record · Phase 3
Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 466
- Enrollment target
NCT00625612 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 466 participants.
The verdict
NCT00625612, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 466 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the safety and effectiveness of one dose strength of Denufosol compared to placebo in patients with CF and a predicted FEV1 of greater than or equal to 75% but less than or equal to 110% predicted.
Interventions
- DRUG Placebo
- DRUG Denufosol Tetrasodium (INS37217) Inhalation Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00625612
The ClinicalTrials.gov registry entry for NCT00625612 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 466 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00625612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00625612 about?
NCT00625612 is a clinical study titled "Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease". The purpose of this trial is to evaluate the safety and effectiveness of one dose strength of Denufosol compared to placebo in patients with CF and a predicted FEV1 of greater than or equal to 75% but less than or equal to 110% predicted.
What is the current status of trial NCT00625612?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 466 participants. The study started on 2008-02. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00625612?
The interventions under investigation include: Placebo (DRUG), Denufosol Tetrasodium (INS37217) Inhalation Solution (DRUG).
Who is sponsoring clinical trial NCT00625612?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.